Table 1 Clinical features of DLBCL patients at the time of diagnosis (n = 74)
From: Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
|
All group (n = 74) |
TP53mut (n = 12) |
TP53wt (n = 62) |
P-value (TP53mut vs. TP53wt) | |
|---|---|---|---|---|
| Mean age (yrs) | 52.8 ± 14.3 | 50.3 ± 10.6 | 58.6 ± 18.5 | 0.347 |
| Sex | 0.403 | |||
| M | 35 | 7 | 28 | |
| F | 39 | 5 | 34 | |
| B-symptoms | 0.016 | |||
| No | 36 | 2 | 34 | |
| Yes | 38 | 10 | 28 | |
| Performance score | 0.352 | |||
| 0 + 1 | 57 | 8 | 49 | |
| 2–3 | 17 | 4 | 13 | |
| Stage | 0.264 | |||
| I-II | 7 | 0 | 7 | |
| III-IV | 67 | 12 | 55 | |
| Extranodal foci | 0.074 | |||
| No | 42 | 4 | 38 | |
| Yes | 32 | 8 | 24 | |
| Splenomegaly | 0.044 | |||
| No | 59 | 7 | 52 | |
| Yes | 15 | 5 | 10 | |
| Bone marrow involvement | 0.028 | |||
| No | 51 | 4 | 47 | |
| Yes | 23 | 8 | 15 | |
| S-LDH | 0.296 | |||
| Normal | 41 | 5 | 36 | |
| Elevated | 33 | 7 | 26 | |
| IPI score | 0.018 | |||
| 0–2 | 21 | 0 | 21 | |
| 3–5 | 53 | 12 | 41 | |
| Therapy response | ||||
| CR | 58 | 7 | 51 | 0.066 |
